Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review

Figures & data

Figure 1 Change in HbA1c percentage, and final HbA1c category, of men with hypogonadism within a German registry analysis over eight years, with or without testosterone therapy. Data from Yassin et al.³²

Figure 2 Yearly cost of inpatient management of hypogonadism-related comorbidities, in an individual treated or untreated with testosterone therapy (TTh).

Yassin A, Haider A, Haider KS, et al. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study. Diabetes Care. 2019;42(6):1104–1111. doi:10.2337/dc18-2388

 PubMed Web of Science ®Google Scholar